ГоловнаArchive of numbers2019Volume 27, issue 2 (99)Problem of interrelations of effi cacy and safety during pharmaco therapy in angioneurology: focus on ginkgo preparations
Title of the article | Problem of interrelations of effi cacy and safety during pharmaco therapy in angioneurology: focus on ginkgo preparations | ||||
Authors |
Burchynskyi Sergiy |
||||
In the section | HELP TO PRACTICAL PHYSICIAN | ||||
Year | 2019 | Issue | Volume 27, issue 2 (99) | Pages | 73-77 |
Type of article | Scientific article | Index UDK | 616.8-005-08 : 615.272 | Index BBK | - |
Abstract | In the present article a modern criteria defi ned the terms "effi cacy" and "safety" during pharmacotherapy in cerebrovascular pathology have been looked. A main risks and possible adverse eff ects of widely used nootropic and vasotropic drugs in angioneurologic practice have been analyzed. Advantages of use the neurotropic phytodrugs and especially preparations of Ginkgo biloba have been looked in details. Use as an optimal instrument of pharmacotherapy in cerebrovascular pathology the drug Bilobil-Intens has been grounded based on the point of view of its complex clinical- pharmacological eff ect and safety criteria. | ||||
Key words | cerebrovascular pathology; pharmacotherapy; phytodrugs; ginkgo biloba preparations; Bilobil | ||||
Access to full text version of the article pdf | download | ||||
Bibliography |
1. Avedisova A. S., Ahapkin R. V., Ahapkina V. I., Verigo N. I. Analiz zarubezhnyh issledovanij nootropnyh preparatov (na primere piracetama) // Rossijskij psihiatricheskij zhurnal. 2001. № 1. S. 46—53.
2. Burchinskij S. G. Nootropy: klassifikaciya, mehanizmy dejstviya, sravnitelnaya harakteristika farmakologicheskih svojstv. Kiev, 2004. 21 s.
3. Burchinskij S. G. Opasnosti i riski nootropnoj farmakoterapii: mif ili realnost? // Racionalnaya farmakoterapiya. 2007. № 1. S. 62—66.
4. Zaharov V. V., Bakulin I. S. Bilobil Intens — nejroprotektivnyj preparat rastitelnogo proishozhdeniya: spektr primeneniya v nevrologii // Nervnye bolezni. 2017. № 1. S. 15—20.
5. Kamchatnov P. R., Chugunov A. V., Umarova H. Ya. Vertebralno-bazilyarnaya nedostatochnost — voprosy diagnostiki i lecheniya // Consilium Medicum. 2005. T. 7, № 2. S. 142—146.
6. Kamchatnov P. R. Vozmozhnosti primeneniya ekstrakta ginkgo biloba (memoplant) v nevrologi ches koj praktike // Zhurnal nevrologii i psihiatrii imeni S. S. Korsakova. 2010. T. 110, № 5. S. 51—56.
7. Kuznecova S. M., Shulzhenko D. V. Ekstrakt ginkgo biloba v strategii lecheniya hronicheskih sosudistyh zabolevanij golovnogo mozga // Mizhnarodnij nevrologichnij zhurnal. 2015. № 2 (72). S. 109—115.
8. Mishenko T. S., Mishenko V. N., Lapshina I. A. Bilobil Intens v lechenii bolnyh s discirkulyatornoj encefalopatiej, oslozhnennoj aterosklerozom i arterialnoj gipertenziej // Tam samo. 2012. № 6. S. 9—14.
9. Mishenko T. S. Epidemiologiya cerebrovaskulyarnyh zabolevanij i organizaciya pomoshi bolnym s mozgovym insultom v Ukraine // Ukrayinskij visnik psihonevrologiyi. 2017. T. 25, vip. 1 (90). S. 22—24.
10. Moskovko S. M. Nootropnij vibir: mirkuvannya z privodu sindromnogo i simptomatichnogo pidhodu // Mizhnarodnij nevrologichnij zhurnal. 2012. № 6. S. 95—98. URL: http://nbuv.gov.ua/UJRN/Mnzh_2012_6_15.
11. Shahparonova N. V., Kadykov A. S. Mesto preparata Bilobil v kompleksnoj terapii sosudistyh zabolevanij golovnogo mozga // Liki Ukrayini. 2010. № 9. S. 54—56.
12. Shtrygol S. Yu., Kortunova T. V., Shtrygol D. V. Pobochnye effekty nootropnyh sredstv // Provizor. 2003. № 11. URL: http://www.provisor.com.ua/archive/2003/N11/art_31.php.
13. Elgood A. L. Use of nootropic drugs in general practice: meta-analysis // J. Clin. Pract. Pharm. 2012. Vol. 9. P. 114—123.
14. Ihl R. Gingko biloba extract EGb 761: clinical data in dementia // Int. Psychogeriatr. 2012. Vol. 24, suppl. 1. P. S35—S40. DOI: 10.1017/S1041610212000543.
15. Kaschel B. Ginkgo biloba: specificity of neuropsychological improvement — a selective review in search of differential effects // Hum. Psychopharmacol. 2009. Vol. 24. P. 343—370. DOI: 10.1002/hup.1037.
16. Koch E. Inhibition of platelet activating factor (PAF)-induced aggregation of human thrombocytes by ginkgolides: considerations on possible bleeding complications after oral intake of Ginkgo biloba extracts // Phytomedicine. 2005. Vol. 12. P. 10—16. DOI: 10.1016/j.phymed.2004.02.002.
17. Lender P. Pharmacotherapy of epilepsy: safety problems // Epilepsia. Modern Aspects of Treatment. Chicago : Illinois Univ Ed., 2010. P. 184—199.
18. Marti-Masso J. F., Poza J. J. Cinnarizine-induced parkinsonism: ten years later // Mov. Disord. 1998. Vol. 13. P. 453—456.
19. Morgenstern C., Biermann E. The efficacy of Gingko biloba special extract EGb 761 in patients with tinnitus // J. Clin. Pharmacol. Ther. 2002. Vol. 40. P. 188—197. PMID: 12051570.
20. Paljk M., Vitezič P., Milharčič Simčič M. Bilobil — clinically confirmed effective and safe Ginkgo biloba medicine satisfying the highest quality standards // Krka Med Farm. 2014; 26 (38):144—154. 21. Schatzberg A. F., Nemeroff C. B. Textbook of Psychopharmaco logy. Washington : Amer. Psychiatr. Ass., 2007. 824 p.
22. Sollier C. B. D., Caplain H., Drouet L. No alteration in platelet function or coagulation induced by EGb761 in a controlled study // Clin. Lab. Haematol. 2003. Vol. 25(4). P. 251—253. PMID:12890165. 23. Stefanache F. The monitoring of the efficiency and safety of Bilobil Intens treatment in patients with moderate and severe cognitive impairment and peripheral blood flow impairment // Rom. J. Neurol. 2011. Vol. 10 (3). P. 154—157.
24. Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and metaanalysis / Tan M. S., Yu J. T., Tan C. C. [et al.] // J. Alzheimer’s Dis. 2015. Vol. 43. P. 589—603. DOI: 10.3233/JAD-140837.
25. Underwood P. K., Lindsey R. Long-term pharmacotherapy in cardiology and cardiovascular risk: how it can be reduced ? // Ann. Cardiovasc. Pharmacol. 2011. Vol. 6. P. 44—60.
26. WHO information. Calcium channel blockers and Parkinson's disease // Drug Inform. 2002. Vol. 23, № 4. P. 27—29.
27. Winblad B. Piracetam: a review of pharmacological properties and clinical use // CNS Drug Rev. 2005. Vol. 11. P. 169—182. PMID: 16007238.
|